310 related articles for article (PubMed ID: 28356715)
1. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
Friend R; Bhutani M; Voorhees PM; Usmani SZ
Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715
[TBL] [Abstract][Full Text] [Related]
2. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
4. Elotuzumab for the treatment of multiple myeloma.
Moreau P; Touzeau C
Future Oncol; 2014 May; 10(6):949-56. PubMed ID: 24941981
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
6. Elotuzumab: First Global Approval.
Markham A
Drugs; 2016 Mar; 76(3):397-403. PubMed ID: 26809244
[TBL] [Abstract][Full Text] [Related]
7. Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
[TBL] [Abstract][Full Text] [Related]
8. Elotuzumab for the treatment of multiple myeloma.
Wang Y; Sanchez L; Siegel DS; Wang ML
J Hematol Oncol; 2016 Jul; 9(1):55. PubMed ID: 27417553
[TBL] [Abstract][Full Text] [Related]
9. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
[TBL] [Abstract][Full Text] [Related]
10. Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.
Grosicki S; Barchnicka A
Expert Rev Hematol; 2016 Jul; 9(7):621-8. PubMed ID: 27322214
[TBL] [Abstract][Full Text] [Related]
11. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
Offidani M; Corvatta L
Future Oncol; 2018 Feb; 14(4):319-329. PubMed ID: 29091475
[TBL] [Abstract][Full Text] [Related]
12. The role of SLAMF7 in multiple myeloma: impact on therapy.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Clin Immunol; 2017 Jan; 13(1):67-75. PubMed ID: 27376202
[TBL] [Abstract][Full Text] [Related]
13. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
[TBL] [Abstract][Full Text] [Related]
14. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Iida S; Nagai H; Kinoshita G; Miyoshi M; Robbins M; Pandya D; Bleickardt E; Chou T
Int J Hematol; 2017 Mar; 105(3):326-334. PubMed ID: 27848182
[TBL] [Abstract][Full Text] [Related]
15. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Laubach J; Richardson P
Expert Opin Biol Ther; 2013 Dec; 13(12):1731-40. PubMed ID: 24151843
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Action and Clinical Development of Elotuzumab.
Ritchie D; Colonna M
Clin Transl Sci; 2018 May; 11(3):261-266. PubMed ID: 29272564
[No Abstract] [Full Text] [Related]
17. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Zamagni E; Tacchetti P; Pantani L; Cavo M
Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
[TBL] [Abstract][Full Text] [Related]
18. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
Veillette A; Guo H
Crit Rev Oncol Hematol; 2013 Oct; 88(1):168-77. PubMed ID: 23731618
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
20. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
Comeau JM; Kelly K; Jean GW
Am J Health Syst Pharm; 2018 Jan; 75(2):55-66. PubMed ID: 29317395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
